21/11/2011: The Federal Minister gives a final decision (positive) for this trial.
Trial reference:
A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)